Back

What is the current role of cardiac magnetic resonance and clinical risk scores in risk stratification for hypertrophic cardiomyopathy?

30 August 2026 (17:30 - 17:45)
Organised by: Logo
Congress Presentation Part of: Personalised risk stratification in cardiomyopathies: where are we now? Risk Factors and Risk Assessment ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Perry Mark Elliott

University College London, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Is the arrhythmogenic right ventricular cardiomyopathy phenotype outdated for risk prediction?
Doctor A. te Riele (Utrecht, NL)
Slides Video
Presentation thumbnail
Genotype or phenotype or both? Current risk prediction in dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy
Associate Professor L. Crotti (Milan, IT)
Slides Video
Presentation thumbnail
Personalised risk stratification in cardiomyopathies: where are we now? - discussion
Video

Access the full session

Session thumbnail
Personalised risk stratification in cardiomyopathies: where are we now?
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:30 CET
You may be interested in
thumbnail
Congress Presentation
Imaging based risk stratification in hypertrophic cardiomyopathy
30 August 2026
thumbnail
Congress Presentation
The challenge of risk stratification in hypertrophic cardiomyopathy: clinical, genetic and imaging insights from a quaternary referral centre
27 August 2023
thumbnail
Congress Session
Sudden cardiac death risk prediction: guidance for everyday practice
12 April 2026
thumbnail
Congress Presentation
Preventing sudden cardiac death in patients with hypertrophic cardiomyopathy.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources